These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 27314293)

  • 1. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.
    Rychlíková J; Vecka M; Jáchymová M; Macášek J; Hrabák P; Zeman M; Vávrová L; Řoupal J; Krechler T; Ák A
    Cancer Biomark; 2016 Jun; 17(1):55-65. PubMed ID: 27314293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
    Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
    Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.
    Ghassem-Zadeh S; Gaida MM; Szanyi S; Acha-Orbea H; Frossard JL; Hinz U; Hackert T; Strobel O; Felix K
    J Transl Med; 2017 Jun; 15(1):126. PubMed ID: 28578701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
    Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
    Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
    Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis.
    Maekawa T; Kamada Y; Ebisutani Y; Ueda M; Hata T; Kawamoto K; Takamatsu S; Mizutani K; Shimomura M; Sobajima T; Fujii H; Nakayama K; Nishino K; Yamada M; Kumada T; Ito T; Eguchi H; Nagano H; Miyoshi E
    World J Gastroenterol; 2016 May; 22(17):4403-10. PubMed ID: 27158210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss.
    Škrha J; Bušek P; Uhrová J; Hrabal P; Kmochová K; Laclav M; Bunganič B; Frič P
    Pancreatology; 2017; 17(1):89-94. PubMed ID: 28027898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of MSX2 mRNA in brush cytology specimens distinguished pancreatic carcinoma from chronic pancreatitis.
    Satoh K; Hamada S; Kanno A; Ishida K; Ito H; Hirota M; Masamune A; Egawa S; Unno M; Shimosegawa T
    Cancer Sci; 2011 Jan; 102(1):157-61. PubMed ID: 20961362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
    Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignancy in chronic pancreatitis: analysis of diagnostic procedures and proposal of a clinical algorithm.
    Rückert F; Brussig T; Kuhn M; Kersting S; Bunk A; Hunger M; Saeger HD; Niedergethmann M; Post S; Grützmann R
    Pancreatology; 2013; 13(3):243-9. PubMed ID: 23719595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma.
    Nakamura S; Sadakari Y; Ohtsuka T; Okayama T; Nakashima Y; Gotoh Y; Saeki K; Mori Y; Nakata K; Miyasaka Y; Onishi H; Oda Y; Goggins M; Nakamura M
    Ann Surg Oncol; 2019 Jul; 26(7):2104-2111. PubMed ID: 30820789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.
    Kolb A; Kleeff J; Guweidhi A; Esposito I; Giese NA; Adwan H; Giese T; Büchler MW; Berger MR; Friess H
    Cancer Biol Ther; 2005 Jul; 4(7):740-6. PubMed ID: 15970685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
    Lai X; Wang M; McElyea SD; Sherman S; House M; Korc M
    Cancer Lett; 2017 May; 393():86-93. PubMed ID: 28232049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer.
    Prokopchuk O; Grünwald B; Nitsche U; Jäger C; Prokopchuk OL; Schubert EC; Friess H; Martignoni ME; Krüger A
    BMC Cancer; 2018 Feb; 18(1):128. PubMed ID: 29394913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients.
    Singh N; Rashid S; Rashid S; Dash NR; Gupta S; Saraya A
    J Cancer Res Clin Oncol; 2020 Apr; 146(4):897-907. PubMed ID: 32146565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma.
    Fania C; Pezzilli R; Melzi d'Eril G; Gelfi C; Barassi A
    Dig Dis Sci; 2018 Apr; 63(4):920-933. PubMed ID: 29417328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.